Michael Lattanzi
Overview
Explore the profile of Michael Lattanzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bupathi M, Garmezy B, Lattanzi M, Kieler M, Ibrahim N, Perk T, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458118
: Determining how a patient with metastatic cancer is responding to therapy can be difficult for medical oncologists, especially with text-only radiology reports. In this investigation, we assess the clinical...
2.
Guercio B, Sarfaty M, Teo M, Ratna N, Duzgol C, Funt S, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4586-4595.
PMID: 37682528
Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered urothelial carcinoma and real-world clinical outcomes with erdafitinib, including on-treatment...
3.
Lattanzi M, Funt S, Rosenberg J
J Clin Oncol
. 2022 May;
40(23):2657-2658.
PMID: 35609227
No abstract available.
4.
Funt S, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo M, et al.
J Clin Oncol
. 2022 Jan;
40(12):1312-1322.
PMID: 35089812
Purpose: Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in...
5.
Lattanzi M, Rosenberg J
Expert Rev Anticancer Ther
. 2020 Jun;
20(7):551-561.
PMID: 32552213
Introduction: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory...
6.
Pavlick A, Blazquez A, Meseck M, Lattanzi M, Ott P, Marron T, et al.
Cancer Immunol Res
. 2019 Nov;
8(1):70-80.
PMID: 31699709
Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine. Despite promising results from early-phase clinical studies in...
7.
Lattanzi M, Balar A
Curr Oncol Rep
. 2019 Feb;
21(3):24.
PMID: 30806823
Purpose Of Review: Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting...
8.
Lattanzi M, Deng F, Chiriboga L, Femia A, Meehan S, Iyer G, et al.
J Immunother Cancer
. 2018 Oct;
6(1):97.
PMID: 30285856
Background: Malignant angiomyolipoma is an uncommon tumor of the class of perivasciular epithelioid cell neoplasms (PEComas). These tumors are characteristically driven by deleterious mutations in the tumor suppressors TSC1 and...
9.
Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim R, et al.
J Natl Cancer Inst
. 2018 Jun;
111(2):180-188.
PMID: 29912415
Background: Two primary histologic subtypes, superficial spreading melanoma (SSM) and nodular melanoma (NM), comprise the majority of all cutaneous melanomas. NM is associated with worse outcomes, which have been attributed...
10.
Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado R, et al.
J Immunother Cancer
. 2018 May;
6(1):38.
PMID: 29773080
Background: Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients...